Uh oh: U.S. health body questions AstraZeneca's COVID vaccine trial data

AstraZeneca may have released outdated information on its latest COVID-19 vaccine trial, giving an “incomplete” picture of its efficacy, a leading U.S. health agency said on Tuesday, casting doubt on the shot’s potential U.S. rollout and plunging its developers, once again, into controversy…

The Data Safety Monitoring Board (DSMB), an independent committee overseeing the trial, has “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” the U.S. National Institute of Allergy and Infectious Diseases (NIAID) said in a statement bit.ly/3scE3ji released after midnight in the United States…

The statement raises fresh questions about the vaccine’s efficacy as it is being administered in dozens of countries worldwide and clouds the timeline for its emergency use authorization in the United States.

“This is indeed an extraordinary act. The negative reports about this vaccine do not stop, although my assessment is that it is well tolerated and safe, but clearly less effective than the two mRNA vaccines,” Peter Kremsner, from the University Hospital in Tuebingen, Germany.